Switchable PDT for reducing skin photosensitization by a NIR dye inducing self-assembled and photo-disassembled nanoparticles

Biomaterials

Volumn 107, Issue , 2016, Pages 23-32

  Zhang, Yifan ^a   He, Lingyi ^a   Wu, Jie ^a   Wang, Kaikai ^a   Wang, Juan ^a   Dai, Weimin ^a   Yuan, Ahu ^a,c   Wu, Jinhui ^a,b,c   Hu, Yiqiao ^a,c  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c NANJING UNIVERSITY   (China)

Author keywords

NIR dye bridge; Photo disassembly; Skin photosensitization; Switchable PDT; Tumor ablation

Indexed keywords

INFRARED DEVICES; PHOTODYNAMIC THERAPY; SELF ASSEMBLY; TUMORS;

INTRAVENOUS ADMINISTRATION; LIGHT IRRADIATIONS; PHOTO-DISASSEMBLY; PHOTODYNAMIC THERAPY (PDT); SWITCHABLE; TUMOR ABLATION; TUMOR INHIBITION; WHOLE-BODY DISTRIBUTIONS;

PHOTOSENSITIZERS;

ALBUMIN; CHLORIN E6; DYE; GOLD NANOROD; IODIDE; NEAR INFRARED DYE IR780; PHOTOSENSITIZING AGENT; SINGLET OXYGEN; UNCLASSIFIED DRUG; 2-(2-(2-CHLORO-3-((1,3-DIHYDRO-3,3-DIMETHYL-1-PROPYL-2H-INDOL-2-YLIDENE)ETHYLIDENE)-1-CYCLOHEXEN-1-YL)ETHENYL)-3,3-DIMETHYL-1-PROPYLINDOLIUM; COLORING AGENT; INDOLE DERIVATIVE; NANOCAPSULE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONJUGATE; EDEMA; ERYTHEMA; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PHOTOTOXICITY; PRIORITY JOURNAL; RABBIT; SKIN; SYNTHESIS; TISSUE DISTRIBUTION; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG EFFECTS; INFRARED RADIATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIVITY DISORDER; PROCEDURES; RADIATION DERMATITIS; RADIATION RESPONSE; THERAPEUTIC USE; TREATMENT OUTCOME;

ANIMALS; COLORING AGENTS; INDOLES; INFRARED RAYS; MALE; MICE; MICE, INBRED BALB C; NANOCAPSULES; PHOTOCHEMOTHERAPY; PHOTOSENSITIVITY DISORDERS; PHOTOSENSITIZING AGENTS; RADIODERMATITIS; SKIN; TREATMENT OUTCOME;

EID: 84984992289     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.08.037     Document Type: Article

References (29)

1. [1] Agostinis, P., et al. Photodynamic therapy of cancer: an update. CA Cancer J. Clin. 61:4 (2011), 250–281.
2. [2] Cheng, L., et al. Functional nanomaterials for phototherapies of cancer. Chem. Rev. 114:21 (2014), 10869–10939.
3. [3] Zhang, H.J., et al. Near-infrared-triggered in situ hybrid hydrogel system for synergistic cancer therapy. J. Mater. Chem. B 3:30 (2015), 6310–6326.
4. [4] Celli, J.P., et al. Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. Chem. Rev. 110:5 (2010), 2795–2838.
5. [5] Allison, R.R., Sibata, C.H., Oncologic photodynamic therapy photosensitizers: a clinical review. Photodiagnosis Photodyn. Ther. 7:2 (2010), 61–75.
6. [6] Pushpan, S.K., et al. Porphyrins in photodynamic therapy - a search for ideal photosensitizers. Curr. Med. Chem. Anticancer Agents 2:2 (2002), 187–207.
7. [7] Ogura, S.-i., et al. Development of phthalocyanines for photodynamic therapy. J. Porphyr. Phthalocyanines 10:09 (2006), 1116–1124.
8. [8] Lovell, J.F., et al. Activatable photosensitizers for imaging and therapy. Chem. Rev. 110:5 (2010), 2839–2857.
9. [9] Lim, C.K., et al. Nanophotosensitizers toward advanced photodynamic therapy of Cancer. Cancer Lett. 334:2 (2013), 176–187.
10. [10] Jang, B., et al. Gold nanorod-photosensitizer complex for near-infrared fluorescence imaging and photodynamic/photothermal therapy in vivo. Acs Nano 5:2 (2011), 1086–1094.
11. [11] Kim, H., et al. ROS-responsive activatable photosensitizing agent for imaging and photodynamic therapy of activated macrophages. Theranostics 4:1 (2013), 1–11.
12. [12] Ichikawa, Y., et al. Selective ablation of beta-galactosidase-expressing cells with a rationally designed activatable photosensitizer. Angew. Chem. Int. Ed. Engl. 53:26 (2014), 6772–6775.
13. [13] Tian, J., et al. A pH-activatable and aniline-substituted photosensitizer for near-infrared cancer theranostics. Chem. Sci. 6:10 (2015), 5969–5977.
14. [14] Chen, H., et al. H2O2-activatable and O2-evolving nanoparticles for highly efficient and selective photodynamic therapy against hypoxic tumor cells. J. Am. Chem. Soc. 137:4 (2015), 1539–1547.
15. [15] Cho, Y., Choi, Y., Graphene oxide-photosensitizer conjugate as a redox-responsive theranostic agent. Chem. Commun. 48:79 (2012), 9912–9914.
16. [16] Cho, Y., Kim, H., Choi, Y., A graphene oxide-photosensitizer complex as an enzyme-activatable theranostic agent. Chem. Commun. (Camb.) 49:12 (2013), 1202–1204.
17. [17] Bansal, A., Zhang, Y., Photocontrolled nanoparticle delivery systems for biomedical applications. Acc. Chem. Res. 47:10 (2014), 3052–3060.
18. [18] Jiang, C., et al. Hydrophobic IR780 encapsulated in biodegradable human serum albumin nanoparticles for photothermal and photodynamic therapy. Acta Biomater. 14 (2015), 61–69.
19. [19] Kratz, F., Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control Release 132:3 (2008), 171–183.
20. [20] Kratz, F., Elsadek, B., Clinical impact of serum proteins on drug delivery. J. Control Release 161:2 (2012), 429–445.
21. [21] Jiang, Y., et al. Albumin-micelles via a one-pot technology platform for the delivery of drugs. Chem. Commun. (Camb.) 50:48 (2014), 6394–6397.
22. [22] Lovell, J.F., et al. FRET quenching of photosensitizer singlet oxygen generation. J. Phys. Chem. B 113:10 (2009), 3203–3211.
23. [23] Jeong, H., et al. Photosensitizer-conjugated human serum albumin nanoparticles for effective photodynamic therapy. Theranostics 1 (2011), 230–239.
24. [24] Yuan, A., et al. Activatable photodynamic destruction of cancer cells by NIR dye/photosensitizer loaded liposomes. Chem. Commun. (Camb.) 51:16 (2015), 3340–3342.
25. [25] Chen, Q., et al. Drug-induced self-assembly of modified albumins as nano-theranostics for tumor-targeted combination therapy. ACS Nano 9 (2015), 5223–5233.
26. [26] Scholes, G.D., Long-range resonance energy transfer in molecular systems. Annu. Rev. Phys. Chem. 54 (2003), 57–87.
27. [27] Miyata, S., et al. Accumulation of pyrraline-modified albumin in phagocytes due to reduced degradation by lysosomal enzymes. J. Biol. Chem. 272:7 (1997), 4037–4042.
28. [28] Nelson, J.S., Roberts, W.G., Berns, M.W., In vivo studies on the utilization of mono-L-aspartyl chlorin (NPe6) for photodynamic therapy. Cancer Res. 47:17 (1987), 4681–4685.
29. [29] Gomer, C.J., Razum, N.J., Acute skin response in albino mice following porphyrin photosensitization under oxic and anoxic conditions. Photochem. Photobiol. 40:4 (1984), 435–439.